🔥FDA has approved Zaynich (cefepime and zidebactam) for adults with complicated urinary tract infections (cUTIs) caused by designated susceptible microorganisms.🔥 www.accessdata.fda.gov/drugsatfda_d...
May 29, 2026 at 7:23 PM
🔥FDA has approved Zaynich (cefepime and zidebactam) for adults with complicated urinary tract infections (cUTIs) caused by designated susceptible microorganisms.🔥 www.accessdata.fda.gov/drugsatfda_d...
In klinischen Tests schlug Zaynich multiresistente Keime in 89 Prozent der Fälle, das Vergleichsmittel Meropenem nur in 68 Prozent. Indiens erstes eigenentwickeltes FDA-Medikament.
Zaynich: Indisches Antibiotikum erhält FDA-Zulassung
Die FDA hat am 29. Mai 2026 Zaynich (Cefepim plus Zidebactam) zugelassen, ein Antibiotikum gegen multiresistente Keime bei schweren Harnwegsinfekten. Es ist das erste vollständig von einem indischen Pharmaunternehmen entdeckte und entwickelte Medikam
denkstrom.org
June 10, 2026 at 8:03 AM
In klinischen Tests schlug Zaynich multiresistente Keime in 89 Prozent der Fälle, das Vergleichsmittel Meropenem nur in 68 Prozent. Indiens erstes eigenentwickeltes FDA-Medikament.
CARB-X welcomes FDA approval of Zaynich for cUTI patients. This new tool to treat MDR infections demonstrates that breakthrough innovation can emerge from diverse ecosystems around the world – a reminder that addressing AMR requires supporting innovators wherever they are. #IDSky
🔗
🔗
How Wockhardt Created India’s First FDA-Approved Novel Antibiotic
For decades, India excelled at making medicines invented elsewhere. With Zaynich, Wockhardt has become the first Indian pharma company to discover, develop, and own an FDA-approved drug
bit.ly
June 10, 2026 at 1:00 PM
CARB-X welcomes FDA approval of Zaynich for cUTI patients. This new tool to treat MDR infections demonstrates that breakthrough innovation can emerge from diverse ecosystems around the world – a reminder that addressing AMR requires supporting innovators wherever they are. #IDSky
🔗
🔗
In klinischen Tests schlug Zaynich multiresistente Keime in 89 Prozent der Fälle, das Vergleichsmittel Meropenem nur in 68 Prozent. Indiens erstes eigenentwickeltes FDA-Medikament.
Zaynich: Indisches Antibiotikum erhält FDA-Zulassung
Die FDA hat am 29. Mai 2026 Zaynich (Cefepim plus Zidebactam) zugelassen, ein Antibiotikum gegen multiresistente Keime bei schweren Harnwegsinfekten. Es ist das erste vollständig von einem indischen Pharmaunternehmen entdeckte und entwickelte Medikam
denkstrom.org
June 27, 2026 at 6:17 PM
In klinischen Tests schlug Zaynich multiresistente Keime in 89 Prozent der Fälle, das Vergleichsmittel Meropenem nur in 68 Prozent. Indiens erstes eigenentwickeltes FDA-Medikament.
India's new antibiotics, including Enmetazobactam, Zaynich, and Nafithromycin, show promise against AMR bugs, but systemic reforms like better prescription practices and infection control are essential to prevent rising resistance.
www.jagonews24.com/en/amp/78870
www.jagonews24.com/en/amp/78870
New breakthrough drugs target deadly superbugs
Antibiotics, once hailed as lifesaving medical marvels, are increasingly losing ground against evolving bacteria that outsmart these drugs. Known as...
www.jagonews24.com
December 5, 2024 at 7:18 PM
India's new antibiotics, including Enmetazobactam, Zaynich, and Nafithromycin, show promise against AMR bugs, but systemic reforms like better prescription practices and infection control are essential to prevent rising resistance.
www.jagonews24.com/en/amp/78870
www.jagonews24.com/en/amp/78870
🚨 New FDA Approval alert!
💊 Cefepime/Zidebactam (Zaynich)
💡 Zidebactam is a bicyclo-acyl hydrazide agent with dual mechanisms including PBP2 inhibition and beta-lactamase inhibition!
#IDXPosts #antibiotic
💊 Cefepime/Zidebactam (Zaynich)
💡 Zidebactam is a bicyclo-acyl hydrazide agent with dual mechanisms including PBP2 inhibition and beta-lactamase inhibition!
#IDXPosts #antibiotic
🔥FDA has approved Zaynich (cefepime and zidebactam) for adults with complicated urinary tract infections (cUTIs) caused by designated susceptible microorganisms.🔥 www.accessdata.fda.gov/drugsatfda_d...
May 31, 2026 at 2:18 PM
🚨 New FDA Approval alert!
💊 Cefepime/Zidebactam (Zaynich)
💡 Zidebactam is a bicyclo-acyl hydrazide agent with dual mechanisms including PBP2 inhibition and beta-lactamase inhibition!
#IDXPosts #antibiotic
💊 Cefepime/Zidebactam (Zaynich)
💡 Zidebactam is a bicyclo-acyl hydrazide agent with dual mechanisms including PBP2 inhibition and beta-lactamase inhibition!
#IDXPosts #antibiotic
The FDA approved intravenous cefepime and zidebactam (Zaynich) for complicated urinary tract infections (UTIs), including pyelonephritis, caused by susceptible gram-negative bacteria in adults, Wockhardt announced.
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/121598
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/121598
Antibiotic Combo Approved for Multidrug-Resistant UTIs
Intravenous cefepime-zidebactam was significantly superior to meropenem in phase III trial
www.medpagetoday.com
June 5, 2026 at 3:04 PM
The FDA approved intravenous cefepime and zidebactam (Zaynich) for complicated urinary tract infections (UTIs), including pyelonephritis, caused by susceptible gram-negative bacteria in adults, Wockhardt announced.
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/121598
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/121598
3 new promising antibiotics developed by Indian scientists have shown potential to fight anti-microbial resistance.
While Enmetazobactam has been approved by FDA, Zaynich and Miqnaf have shown very good results in advanced clinical trials.
#science #antibiotics #amr
www.bbc.co.uk/news/article...
While Enmetazobactam has been approved by FDA, Zaynich and Miqnaf have shown very good results in advanced clinical trials.
#science #antibiotics #amr
www.bbc.co.uk/news/article...
India's 'blockbuster' drugs to combat antibiotic-resistant superbugs - BBC News
A number of promising new drugs from India show potential to fight antibiotic-resistant bacteria.
www.bbc.co.uk
December 5, 2024 at 5:31 PM
3 new promising antibiotics developed by Indian scientists have shown potential to fight anti-microbial resistance.
While Enmetazobactam has been approved by FDA, Zaynich and Miqnaf have shown very good results in advanced clinical trials.
#science #antibiotics #amr
www.bbc.co.uk/news/article...
While Enmetazobactam has been approved by FDA, Zaynich and Miqnaf have shown very good results in advanced clinical trials.
#science #antibiotics #amr
www.bbc.co.uk/news/article...
.@RichhariyaSneha ✍️ in @ThePrintIndia on India’s first FDA approved antibiotic #Zaynich
💠Insights: @KaminiWalia @ICMRdelhi, Dr NK Ganguly, @DrSingh_AIIMS, Bhakti AMR survivor, @Shobha1Shukla @globalAMRmedia
The Print 👇
theprint.in/health/wockh...
#AntimicrobialResistance #AMR
💠Insights: @KaminiWalia @ICMRdelhi, Dr NK Ganguly, @DrSingh_AIIMS, Bhakti AMR survivor, @Shobha1Shukla @globalAMRmedia
The Print 👇
theprint.in/health/wockh...
#AntimicrobialResistance #AMR
June 5, 2026 at 7:28 AM
.@RichhariyaSneha ✍️ in @ThePrintIndia on India’s first FDA approved antibiotic #Zaynich
💠Insights: @KaminiWalia @ICMRdelhi, Dr NK Ganguly, @DrSingh_AIIMS, Bhakti AMR survivor, @Shobha1Shukla @globalAMRmedia
The Print 👇
theprint.in/health/wockh...
#AntimicrobialResistance #AMR
💠Insights: @KaminiWalia @ICMRdelhi, Dr NK Ganguly, @DrSingh_AIIMS, Bhakti AMR survivor, @Shobha1Shukla @globalAMRmedia
The Print 👇
theprint.in/health/wockh...
#AntimicrobialResistance #AMR
#SmartStocks | 💊 Wockhardt’s experimental drug, Zaynich, has shown impressive results, achieving a 100% cure rate in clinical trials for drug-resistant infections.
Biggest challenge now: can it turn this scientific breakthrough into a financial one?
indianexpress.com/article/smar...
Biggest challenge now: can it turn this scientific breakthrough into a financial one?
indianexpress.com/article/smar...
January 16, 2025 at 11:30 AM
#SmartStocks | 💊 Wockhardt’s experimental drug, Zaynich, has shown impressive results, achieving a 100% cure rate in clinical trials for drug-resistant infections.
Biggest challenge now: can it turn this scientific breakthrough into a financial one?
indianexpress.com/article/smar...
Biggest challenge now: can it turn this scientific breakthrough into a financial one?
indianexpress.com/article/smar...
Enmetazobactam, developed by Chennai-based Orchid Pharma
Mumbai-based Wockhardt is testing a new antibiotic, called Zaynich
Bengaluru-based biopharma firm Bugworks Research
Hyderabad-based Aurigene Pharmaceutical Services
Distributed intelligence!👏🏽👏🏽👏🏽
www.bbc.com/news/article...
Mumbai-based Wockhardt is testing a new antibiotic, called Zaynich
Bengaluru-based biopharma firm Bugworks Research
Hyderabad-based Aurigene Pharmaceutical Services
Distributed intelligence!👏🏽👏🏽👏🏽
www.bbc.com/news/article...
India's 'blockbuster' drugs to combat antibiotic-resistant superbugs
A number of promising new drugs from India show potential to fight antibiotic-resistant bacteria.
www.bbc.com
December 5, 2024 at 4:30 AM
Enmetazobactam, developed by Chennai-based Orchid Pharma
Mumbai-based Wockhardt is testing a new antibiotic, called Zaynich
Bengaluru-based biopharma firm Bugworks Research
Hyderabad-based Aurigene Pharmaceutical Services
Distributed intelligence!👏🏽👏🏽👏🏽
www.bbc.com/news/article...
Mumbai-based Wockhardt is testing a new antibiotic, called Zaynich
Bengaluru-based biopharma firm Bugworks Research
Hyderabad-based Aurigene Pharmaceutical Services
Distributed intelligence!👏🏽👏🏽👏🏽
www.bbc.com/news/article...
“Another ongoing challenge is keeping pace with new antibiotic approvals..between submission and publication of the 2026 guidance, intravenous cefepime-zidebactam (Zaynich) and oral tebipenem (Utebzi) were approved, and we anticipate addressing both in the next update” www.healio.com/news/infecti...
IDSA updates guidance on resistant gram-negative infections
The Infectious Diseases Society of America has updated its guidance on the treatment of antimicrobial-resistant gram-negative infections in the United States.
The new guidance refreshes updates made i...
www.healio.com
August 28, 2026 at 12:28 PM
“Another ongoing challenge is keeping pace with new antibiotic approvals..between submission and publication of the 2026 guidance, intravenous cefepime-zidebactam (Zaynich) and oral tebipenem (Utebzi) were approved, and we anticipate addressing both in the next update” www.healio.com/news/infecti...
India:Wockhardt's Zaynich became India's first homegrown new chemical entity (NCE) approved by the USFDA after over 25 years of research and $800 million in R&D. Wockhardt, Glenmark and Suven have invested over $1.5 billion in drug
August 1, 2026 at 10:52 PM
India:Wockhardt's Zaynich became India's first homegrown new chemical entity (NCE) approved by the USFDA after over 25 years of research and $800 million in R&D. Wockhardt, Glenmark and Suven have invested over $1.5 billion in drug
The result is Zaynich, a novel intravenous antibiotic designed to treat complex urinary tract infections. Wockhardt estimates the drug could eventually generate annual sales of as much as $2 billion. shows India’s biggest constraint in innovation is not a shortage of
July 26, 2026 at 10:57 AM
The result is Zaynich, a novel intravenous antibiotic designed to treat complex urinary tract infections. Wockhardt estimates the drug could eventually generate annual sales of as much as $2 billion. shows India’s biggest constraint in innovation is not a shortage of
▲ NSE:WOCKPHARMA Wockhardt: FY26 revenue of INR3,373 crore and EBITDA of INR630 crore (51% growth), with net debt-to-equity of 0.1 and cash equivalents of INR662 crore. The US FDA approval of Zaynich, its first novel antibiotic, and strong growth in emerging marke...
June 11, 2026 at 7:46 AM
▲ NSE:WOCKPHARMA Wockhardt: FY26 revenue of INR3,373 crore and EBITDA of INR630 crore (51% growth), with net debt-to-equity of 0.1 and cash equivalents of INR662 crore. The US FDA approval of Zaynich, its first novel antibiotic, and strong growth in emerging marke...
▲ NSE:WOCKPHARMA Wockhardt Limited: FY26 income surged 51% YoY to ₹3,373 Cr, with EBITDA margin expanding to 18.6% from 5.4% in FY22-23. The US FDA approval of Zaynich, the first Indian-discovered drug from lab bench to approval, is a transformative catalyst [BULL...
June 4, 2026 at 12:32 PM
▲ NSE:WOCKPHARMA Wockhardt Limited: FY26 income surged 51% YoY to ₹3,373 Cr, with EBITDA margin expanding to 18.6% from 5.4% in FY22-23. The US FDA approval of Zaynich, the first Indian-discovered drug from lab bench to approval, is a transformative catalyst [BULL...
Its dual PBP activity and in vitro activity against MDR Gram-negatives, including MBL producers, make it a noteworthy carbapenem-sparing option. 🔬💊
Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis
ZAYNICH is a multi- penicillin-binding protein targeting combination of the 4th generation cephalosporin cefepime and zidebactam working synergistically...
www.prnewswire.com
June 1, 2026 at 2:11 PM
Its dual PBP activity and in vitro activity against MDR Gram-negatives, including MBL producers, make it a noteworthy carbapenem-sparing option. 🔬💊
🚨 New antibiotic approval! The FDA has approved cefepime-zidebactam (Zaynich) for complicated UTI & pyelonephritis.
June 1, 2026 at 2:11 PM
🚨 New antibiotic approval! The FDA has approved cefepime-zidebactam (Zaynich) for complicated UTI & pyelonephritis.
CAN INDIA`S NEW ANTIBIOTIC ZAYNICH CHANGE THE GLOBAL FIGHT AGAINST SUPERBUG
India’s Wockhardt has unveiled Zaynich, a breakthrough antibiotic that has shown exceptional success against multi-drug-resistant Gram-negative bacteria.
FIRST POST
October 6, 2025, 18:04:06 IST
India’s Wockhardt has unveiled Zaynich, a breakthrough antibiotic that has shown exceptional success against multi-drug-resistant Gram-negative bacteria.
FIRST POST
October 6, 2025, 18:04:06 IST
October 6, 2025 at 3:20 PM
CAN INDIA`S NEW ANTIBIOTIC ZAYNICH CHANGE THE GLOBAL FIGHT AGAINST SUPERBUG
India’s Wockhardt has unveiled Zaynich, a breakthrough antibiotic that has shown exceptional success against multi-drug-resistant Gram-negative bacteria.
FIRST POST
October 6, 2025, 18:04:06 IST
India’s Wockhardt has unveiled Zaynich, a breakthrough antibiotic that has shown exceptional success against multi-drug-resistant Gram-negative bacteria.
FIRST POST
October 6, 2025, 18:04:06 IST
In his @hindustan-times.bsky.social column #VitalSigns, OHT’s Dr. Ramanan Laxminarayan details how Wockhardt's new antibiotic #Zaynich marks a major milestone in the fight to control #AMR. He calls for continued investment in R&D & infection prevention to preserve these life-saving medicines.
Read
Read
India's next pharmaceutical revolution
Wockhardt's new antibiotic marks a turning point for an industry that has typically worked on producing cheaper versions of medicines invented elsewhere
www.hindustantimes.com
July 9, 2026 at 8:00 AM
In his @hindustan-times.bsky.social column #VitalSigns, OHT’s Dr. Ramanan Laxminarayan details how Wockhardt's new antibiotic #Zaynich marks a major milestone in the fight to control #AMR. He calls for continued investment in R&D & infection prevention to preserve these life-saving medicines.
Read
Read